All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:
Diagnosed HCAP events due to S.aureus
Diagnosed BSI events due to CoNS
Diagnosed BSI events due to S.aureus
Diagnosed BSI events due to Enterococccus spp.
Diagnosed BSI events due to other gram-positive
Diagnosed cIAI events due to S.aureus
Diagnosed cIAI events due to CoNS
… and many more (details available on request).
Note: Coverage may vary by country and region.

Table of contents

  • Hospital-Treated Gram-Positive Infections - Epidemiology - Asia Pacific Data
    • Introduction
      • Key Findings
        • Overview
          • Diagnosed UTI Events per 1,000 People of All Ages in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in Diagnosed UTI Events in the Next Ten Years
      • Epidemiology Data
      • Methods
        • Diagnosed UTI Events
        • Diagnosed NP Events
        • Diagnosed BSI Events
        • Diagnosed cIAI Events
        • Diagnosed cSSSI Events
        • Diagnosed SSI Events
        • Gram-Positive Pathogen Distribution
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Hospital-Treated Infections
          • Studies Excluded from the Analysis of Hospital-Treated Infections
        • Risk/Protective Factors
          • Risk/Protective Factors for Hospital-Treated Infections
        • Bibliography

    Author(s): Mariah Scott; T.J. Arndt, M.P.H., C.P.H.

    Mariah J. Scott, M.S., M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, Mariah investigated patient-reported outcomes on health-related quality of life during the transition from pediatric to adult care in patients with Sickle Cell Disease throughout the state of New Jersey.

    Mariah received her B.S. in Molecular Biology from Montclair State University and her M.S. from Seton Hall University where she studied Microbiology and Immunology. Ms. Scott also holds a M.P.H. in Epidemiology from Rutgers University.

    Thomas J. Arndt, M.P.H., C.P.H., is an epidemiologist at DRG, part of Clarivate. He earned his master's degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.